Delving into the Latest Updates on Tallikut Pharmaceuticals, Inc. with Synapse

概览

关联

1

项与 Tallikut Pharmaceuticals, Inc. 相关的药物

Atreleuton

阿曲留通

靶点

5-LOX

作用机制

5-LOX抑制剂

在研机构-

原研机构

Abbott Laboratories

在研适应症-

非在研适应症

急性冠状动脉综合征 [+6]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

3

项与 Tallikut Pharmaceuticals, Inc. 相关的临床试验

NCT00552188

/ Completed临床2期

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event

The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on vascular inflammation following 24 weeks of dosing.

开始日期2007-10-01

申办/合作机构

Tallikut Pharmaceuticals, Inc.

[+5]

NCT00352417

/ Completed临床2期

A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Effects of VIA-2291, a 5-Lipoxygenase Inhibitor, on Atherosclerotic Plaque and Biomarkers of Vascular Inflammation in Patients With Carotid Stenosis Undergoing Elective Carotid Endarterectomy

This is a study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with carotid stenosis scheduled for elective carotid endarterectomy

开始日期2006-07-01

申办/合作机构

Tallikut Pharmaceuticals, Inc.

NCT00358826

/ Completed临床2期

Clinical Study Protocol No. VIA-2291-01, A Phase 2 Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-ranging Study of the Effect of VIA-2291 on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event

This is a dose ranging study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with recent acute coronary events

开始日期2006-07-01

申办/合作机构

Tallikut Pharmaceuticals, Inc.

[+1]

100 项与 Tallikut Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Tallikut Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Tallikut Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Tallikut Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息